State Prescription Drug Purchase Standards | ||||||||||||||||||||||
| Results | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||
Results by county
| ||||||||||||||||||||||
| Source: California Secretary of State[1] | ||||||||||||||||||||||
Proposition 61 was a California ballot proposition that appeared on the November 8, 2016 ballot. It would have prohibited the state of California from buying any prescription drug from a drug manufacturer at price over the lowest price paid for the drug by the United States Department of Veterans Affairs. It would have exempted managed care programs funded through Medi-Cal.[2] According to the fiscal impact statement issued by California Legislative Analyst's Office, "potential for state savings of an unknown amount depending on (1) how the measure’s implementation challenges are addressed and (2) the responses of drug manufacturers regarding the provision and pricing of their drugs."[3]
Proposition 61 was rejected by a vote of 47 to 53 percent.[4]
| Poll source | Date(s) administered |
Sample size |
Margin of error |
% support | % opposition | % Undecided/Don't Know |
|---|---|---|---|---|---|---|
| Field/YouGov | October 25–31, 2016 | 998 LV | N/A | 47% | 47% | 6% |
| Hoover Institution/YouGov | October 4–14, 2016 | 1248 LV | ± 3.28% | 51% | 24% | 25% |
| Field/YouGov | September 7–13, 2016 | 943 LV | N/A | 50% | 16% | 34% |
| USC Dornsife/Los Angeles Times[note 1] | September 1–8, 2016 | 1912 RV | ± 3% | 66% | 23% | 12% |
 | This article about the politicsofCalifornia is a stub. You can help Wikipedia by expanding it. |
